



**BSD MEDICAL**

- Home
- Company
- International
- Physicians
- Products
- Investors
- Links

A Company Specializing in BioSystem

### Press Releases

## ASCO Presentations Show Hyperthermia Enhances Car Delivery

SAN FRANCISCO, May 17, 2001—BSD Medical Corp. (OTCBB:BSDM). Hyperthermia dra increases the uptake of chemotherapy drugs by cancer cells. This message was repeate Francisco at the American Society of Clinical Oncologists (ASCO) just concluded, the lar related medical convention in the world, with over 30,000 physicians and other medical attendance. According to a research team from Munich, this boost in the effectiveness c is good news for victims of high-risk soft-tissue sarcomas, one of the deadliest and mos forms of cancer. It is also good news for treatment of breast cancer, according to a rese the University of California, San Francisco and another from Athens, Greece, and for ov where clinical trials underway at Duke University point to new breakthroughs.

When the temperature of tumors is raised to high-fever level (hyperthermia), tumors b more absorbent to chemotherapy drugs. Increased blood flow is the body's natural resp raising the uptake of drugs in tumor membranes. As a result, hyperthermia "increases c antitumor efficacy in patients," according to the UCSF team. Once drugs are delivered, l also be used as an activator to accelerate drug chemical reactions. Hyperthermia is furt demonstrating a role as a valuable companion therapy when chemotherapy drugs are ir blood in encapsulated form (liposomes). Research has shown that when a liposome-enc used in combination with hyperthermia, tumor drug penetration greatly increases.

Dr. Rolf Issels of Munich University Medical School and GSF National Research Center of and Health made an advanced private presentation of his team's important paper at a s symposium sponsored by BSD Medical Corporation. Accompanying him were Dr. Zeljko Duke University Medical Center and Dr. Joan Bull of the University of Texas, Houston He Center, who also gave a private review of her paper in advance of formal presentation. reviewed research with liposomes and hyperthermia, and the use of hyperthermia in he therapy at Duke University. Dr. Bull focused on the important enhancement of hyperthe chemotherapy in fighting metastasis.

Hyrum A. Mead, President of BSD Medical Corporation said, "We are very pleased with t interest in use of hyperthermia in combination with chemotherapy. In fact, a significant the clinical oncologists in America have personally requested information from BSD abo our private symposium, and several of those who attended are already pursuing BSD h systems."

BSD Medical Corporation [BSDM] is the leading developer of hyperthermia systems for r and pioneer of non-surgical benign prostate treatment using microwave energy. For info BSD Medical, or to find hyperthermic oncology information sources and treatment cente site ([www.bsdmc.com](http://www.bsdmc.com)).

Search:



To automatically receive all  
Press Releases via email

First Name:

**please submit the following:**

Last Name:

Email Address:

Organization:

BSD Medical

2188 West 2200 South

Salt Lake City, UT 84119-1326

Phone: 801-972-5555

Fax: 801-972

**COMPANY:** [Company P](#)

**INTERNATIONAL:** [BSD 2000/3D](#) | [BSD 2000/3D](#) |

**PHYSICIANS:** [Hyperthermia as a Cancer Therapy](#) | [Clinical Reports](#) | [Advanced & Recurrent Cancer](#) | [Medical Reimburseme](#)

**PRODUCT:**

**INVESTORS:** [Stock Quote](#) | [Company Profile](#) | [Financial Report](#) | [Directors & Officers](#) | [Market Makers](#) | [Code of Ethics](#) | [Forw](#)

---

Copyright © 2005 BSD Medical Corpor